Peptide Blend
TAS
A clinic-used immune support blend centered on Thymosin Alpha-1 and LL-37. It is discussed for immune modulation, inflammation support, and tissue repair, but the combination is not FDA-approved and human evidence for the blend itself remains limited.
Immune SupportAnti InflammationInjury Healing Blend
Detail
Overview
A clinic-used immune support blend centered on Thymosin Alpha-1 and LL-37. It is discussed for immune modulation, inflammation support, and tissue repair, but the combination is not FDA-approved and human evidence for the blend itself remains limited.
Benefits list
- Immune support
- May reduce inflammation
- Supports tissue repair
Side effects
- Injection site irritation
- Fatigue
- Flu-like symptoms
Vendor protocol
- LL-37 100 mcg SC daily + TA-1 1.6 mg SC 2-3x weekly
- TA-1 1.6-3.2 mg SC twice weekly + LL-37 2-5 mg SC three times weekly; TA-1 first, LL-37 2-3h later
- SC once or several times weekly
Clinical protocol
- None listed
Evidence
- Low
- The individual components have human data, but the TA-1 + LL-37 blend itself is mainly supported by clinic-reported use and early-stage research.
Regulatory
- Not Fda Approved
Research
Mechanisms
Thymic SupportImmune Modulation
Evidence notes
- Low
- The individual components have human data, but the TA-1 + LL-37 blend itself is mainly supported by clinic-reported use and early-stage research.
Administration
InjectableSubcutaneous
Research links
- https://pmc.ncbi.nlm.nih.gov/articles/PMC7747025/
- https://pubmed.ncbi.nlm.nih.gov/17805349/
- https://www.newaira.co/treatment/ta-1-ll-37
Contraindications
- None listed
Components
- Thymosin-alpha-1
- Ll-37
Regulatory data
- Not Fda Approved
Aliases
- TA-1 + LL-37
- Thymosin Alpha-1 + LL-37
- Immune defense blend
Educational reference only. Pepperz does not provide medical advice, diagnosis, treatment, prescribing guidance, or dosing recommendations.